HeartBeam, Inc. received a deficiency letter from Nasdaq notifying the company's common stock has failed to meet the minimum $1.00 bid price requirement for continued listing on the Nasdaq Capital Market. The company has a 180-day compliance period ending December 28, 2026, to regain compliance by maintaining a $1.00 closing bid price for ten consecutive business days. HeartBeam, Inc. is a medical technology company that develops non-invasive optical sensor technology for heart rate and heart rate variability monitoring.

Heartbeam, Inc. announced the departure of CEO Robert P. Eno, effective June 30, 2026, as part of a strategic reorganization. Following his departure, Branislav Vajdic, Ph.D., the company's Founder and President, will serve as the principal executive officer effective July 1, 2026. Mark Strome also resigned from the Board of Directors immediately. Heartbeam, Inc. is a medical technology company that develops software-based optical sensor technology for heart rate monitoring.

On June 15, 2026, HeartBeam, Inc. Board of Directors approved compensatory arrangements for President, Founder and Director Dr. Branislav Vajdic, including a 2,800,000 performance-based restricted stock unit award and a transaction bonus agreement based on market capitalization and per-share price thresholds. HeartBeam, Inc. is a medical technology company that develops software and hardware for non-invasive heart monitoring.